NCT03404115View on ClinicalTrials.gov

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

July 11, 2018

Study Completion Date

July 11, 2018

Conditions
Dry Eye Syndrome
Interventions
DRUG

Reproxalap Ophthalmic Solution (0.25%)

Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.

DRUG

Reproxalap Ophthalmic Solution (0.1%)

Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.

DRUG

Vehicle Ophthalmic Solution

Vehicle Ophthalmic Solution administered for approximately twelve weeks.

Trial Locations (6)

38119

Total Eye Care, Memphis

46290

Midwest Cornea Associates, Indianapolis

06708

The Eye Care Group, Waterbury

04240

Central Maine Eye Care, Lewiston

01810

Andover Eye Associates, Andover

02767

Andover Eye Associates, Raynham

Sponsors
All Listed Sponsors
lead

Aldeyra Therapeutics, Inc.

INDUSTRY